Menopause

A recap of the top stories from August 2026 in women's health.

Take a look back at some of the top FDA and pipeline news in women's health from August 2026.

TMP-SMX was linked to higher UTI treatment failure vs. nitrofurantoin and fosfomycin in postmenopausal women.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

A new cohort study links estrogen-only MHT use to reduced Alzheimer disease pathology.

A new LifeStance survey finds many women are unaware that perimenopause can affect mental health.

Women with type 2 diabetes reported more and worse menopause symptoms, especially in the postmenopause stage.

AbCellera's ABCL635 met primary efficacy endpoints in a Phase 2 trial for moderate-to-severe hot flashes.

Semaglutide showed broad menstrual adverse event signals in a FAERS analysis of reproductive-aged patients.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

One in 3 US women aged 35 and older is unsure if they’re in perimenopause, driven by symptom confusion and care barriers.

A pilot trial found nicotinamide riboside and pterostilbene cut hot flashes, bloating, and poor sleep by 50% or more in 7 days.

The SELF-GYN1 trial found that at-home transvaginal ultrasonography met diagnostic quality standards in 96.2% of scans and was significantly preferred by participants over in-clinic imaging.

A 12-week randomized trial found a standardized saffron extract improved mood, self-esteem, and sleep outcomes in menopausal women vs placebo.

A cross-sectional study published in Menopause found that while overall symptom burden was higher in women with average-age menopause, psychological and urogenital symptom scores did not differ significantly.

A reader-driven look at the 10 most-viewed articles on Contemporary OB/GYN from the first half of 2026, spanning FDA decisions, clinical research, and emerging treatments across menopause, contraception, endometriosis, and pelvic health.

A study published in Frontiers in Public Health and led by Mount Sinai researchers found that postmenopausal women in lower-income neighborhoods experienced up to 3.8 times greater bone mineral density loss from air pollution exposure than women in wealthier areas, based on data from 9041 participants in the Women's Health Initiative.

A recap of the top-performing, most-viewed Contemporary OB/GYN stories from June 2026, including new SMFM guidance on acetaminophen in pregnancy, ACOG's break from federal vaccine recommendations, and our coverage of SLEEP 2026 in Baltimore.

A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.

A look ahead to the second half of 2026 for ob-gyns, including Viatris's pending FDA decision on a low-dose estrogen contraceptive patch and previews of the IDSOG, AUGS PFD Week, and The Menopause Society annual meetings.

Shared decision-making around nonhormonal VMS and sleep management requires moving through contraindications, patient preferences, and monitoring burdens together, with elinzanetant's (Lynkuet) dual receptor profile making it a particularly relevant option for women with both VMS and sleep disruption—and with follow-up at 2 to 3 months essential to evaluating response, according to Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF.

Fiona C. Baker, PhD, explains how menopausal sleep disturbance differs from other forms of sleep disruption, citing the role of vasomotor symptoms, hormone changes, and an increased postmenopausal risk of sleep apnea in driving nighttime awakenings.

Among SWAN participants, sleep disturbance was independently associated with lower HRQoL relating to role-physical, role-emotional, and energy/fatigue, with no change in these associations over time.

Jessia Gaulton, MD, MPH, speaks to knowledge and gaps surrounding the menopause transition and mental health associations, while highlighting new Menopause Hub resources from FamilyWell Health.

In part 2 of our discussion with Fiona Baker, PhD, she details how to interpret data from the NIRVANA study, which revealed reductions in wakefulness after sleep onset in the elinzanetant group vs placebo.